Eli Lilly announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference, highlighting new clinical evidence on Kisunla (donanemab-azbt), including long-term safety and biomarker data. The company also shared promising results comparing P-tau217 blood tests to amyloid PET scans for early Alzheimer's detection in cognitively unimpaired individuals, suggesting a more accessible diagnostic option. These findings underscore Lilly's 35-year commitment to advancing Alzheimer's research and treatment. Presentations will be available online after the conference in London from July 12-15, 2026.
In Q2 2026, Eli Lilly reported a strong 48% revenue growth driven by blockbuster obesity drugs Mounjaro and Zepbound, especially with rapid international expansion. Novo Nordisk faced challenges including shrinking U.S. sales, price cuts, layoffs, an...
Vanguard Growth Index Fund Admiral Shares (VIGAX) is heavily concentrated, with about 44.6% of its assets in just four mega-cap tech stocks: NVIDIA, Apple, Alphabet, and Microsoft. This concentration means investors are effectively making a large bet...
Eli Lilly projects fiscal 2026 revenue between $85 billion and $87 billion, nearing the $100 billion mark. The company's stock is up nearly 78% over the past year, driven by strong Q2 2026 results including $22.97 billion revenue and significant sale...
The FDA has approved a new blood test developed by Roche and Eli Lilly to help identify Alzheimer's disease symptoms in patients over 55. The Elecsys Phospho-Tau (217P) Plasma test detects amyloid pathology, a brain marker linked to Alzheimer's, usin...
Eli Lilly has introduced Foundayo, an oral GLP-1 pill for weight loss and type 2 diabetes, in UK pharmacies following recent approval. This tablet offers a convenient alternative to injections and is licensed for adults with certain BMI criteria or w...
